Análise de custo-efetividade da toxina onabotulínica A no tratamento preventivo da migrânea crônica sob a perspectiva do sistema privado de saúde do Brasil

Piovesan, Elcio; Cadecaro, Patricia; Pepe, Camila.
J. bras. econ. saúde (Impr.) ; 9(Suplemento 1): http://www.jbes.com.br/images/v9ns1/71.pdf, Setembro/2017.
Artigo em Inglês | ECOS, LILACS | ID: biblio-859641

Documentos relacionados

  1. Statement of the Rehabilitation Medicine Society of Australia and New Zealand for the therapeutic use of botulinum toxin A in spasticity management.
  2. Botulinum toxin therapy: past, present and future developments.
  3. Potency of botulinum toxin drugs: test systems and labelling.
  4. Review of Botulinum Toxin Uptake and Novel Theory Regarding Potential Spread Days After Injection.
  5. Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA.
  6. Revolutionizing Neck Rejuvenation: ABO Botulinum Toxin A Solution in Multipoint Technique and NASHA Gel Skinbooster.
  7. Adverse effect of botulinum toxin-A injections on mandibular bone: A systematic review and meta-analysis.
  8. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
  9. OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients.
  10. Quantitative Assessment of the Effects of Botulinum Toxin on Skin Perfusion by Laser Doppler Flowmetry: A Clinical Trial.